Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (5916)	11/27/2000 10:00:46 PM
From: shakedown	Read Replies (4) \| Respond to of 14101

Wolf, I think this is the release you speak of: DJ Dimethaid Sees PENNSAID Sales Starting In March [DMX.TO] By Paul Haavardsrud Of DOW JONES NEWSWIRES TORONTO (Dow Jones)--After getting final marketing approval from the U.K. Medicines Control Agency, Dimethaid Research Inc. (T.DMX) expects to begin selling its lead product, PENNSAID Lotion, in the U.K. in March, the company's top executive said. "We are in the home stretch with respect to determining our marketing partner in the U.K.," said Rebecca Keeler, the company's president and chief executive. "We're expecting to launch in the U.K. in the spring, so sometime in March." In a news release, Dimethaid said it will immediately seek approvals for PENNSAID from other European Union countries. Under the mutual recognition procedure prevailing in the EU, the U.K. will act as agent for other EU member states, who can recognize this approval and issue their own authorizations. "Because the British regulatory agency is so well-recognized in Europe, we don't anticipate any negative responses when they submit on our behalf to the other countries," Keeler said, noting that submissions for approval will be made in January to Germany, France, Italy, Sweden and Switzerland, with other European countries to follow. Submissions for approval take 90 days to be processed, under the mutual-recognition procedure, Keeler said. In Toronto trading Monday, Dimethaid is up 0.90, or 20%, to 5.40 on about 573,000 shares. Company Web Site: dimethaid.com